Key Points
- LifeStance CTO Vukasin Paunovich sold 42,067 shares at an average price of $12.87, generating $541,402.29 and reducing his ownership by 17% to 205,379 shares. He also sold $481,674.90 worth of stock in August.
- LifeStance reported quarterly EPS of $0.06, beating estimates by $0.03, while revenue reached $435.35 million, up 26.1% year over year and above expectations.
- Analysts maintain a “Moderate Buy” consensus with a $12.38 average price target; the stock opened at $12.73 and is predominantly held by institutions, which own 85.5% of shares.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) CTO Vukasin Paunovich sold 42,067 shares of LifeStance Health Group stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the sale, the chief technology officer owned 205,379 shares in the company, valued at $2,643,227.73. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.
Vukasin Paunovich also recently made the following trade(s):
- On Monday, August 10th, Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock. The shares were sold at an average price of $10.85, for a total value of $481,674.90.
LifeStance Health Group Trading Down 0.8%
NASDAQ LFST opened at $12.73 on Friday. The stock has a market capitalization of $4.94 billion, a price-to-earnings ratio of 97.93 and a beta of 1.22. The business's fifty day moving average is $11.49 and its 200-day moving average is $8.80. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. LifeStance Health Group, Inc. has a one year low of $4.77 and a one year high of $13.15.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The firm's quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.01) earnings per share. Equities research analysts predict that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its stake in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock worth $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV bought a new stake in shares of LifeStance Health Group in the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC raised its holdings in LifeStance Health Group by 359.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock worth $44,000 after purchasing an additional 5,404 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock worth $59,000 after purchasing an additional 7,987 shares during the period. Finally, Assetmark Inc. boosted its stake in shares of LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company's stock valued at $60,000 after purchasing an additional 1,367 shares in the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research firms recently commented on LFST. KeyCorp upped their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. Canaccord Genuity Group boosted their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. BTIG Research increased their price target on LifeStance Health Group from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, August 19th. Barclays lifted their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, July 14th. Finally, The Goldman Sachs Group began coverage on shares of LifeStance Health Group in a report on Friday, June 5th. They set a "neutral" rating and a $9.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.38.
Read Our Latest Stock Analysis on LFST
LifeStance Health Group Company Profile
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
